First AMBAR® Center opens, one more step in the research and fight against Alzheimer's disease
Based in Barcelona, Spain, the center applies AMBAR® procedure in clinical practice and collects real-world data on the treatment for the disease.
Managed by the Ace Alzheimer Center Barcelona, a renowned non-profit entity whose healthcare professionals are trained and experienced in AMBAR®, the center combines Grifols' more than 15 years of research and know-how in developing the AMBAR® procedure with the Ace Alzheimer Center Barcelona's expertise in diagnosing and treating Alzheimer's patients.
In clinical trials, AMBAR® has shown to reduce disease progression in patients with mild-to-moderate Alzheimer's, as well as a reduction in decline in memory, orientation and judgment.
The treatment protocol consists of a series of outpatient plasma exchange procedures whereby a patient's blood circulates through a medical device that removes the plasma and returns the blood cells to the patient along with an albumin solution. Through this procedure beta-amyloid, a protein that accumulates in the brain and causes neuronal damage, can be eliminated, in addition to other molecules altered by the disease. Furthermore, the infused albumin could exert beneficial effects due to its immunomodulatory and anti-inflammatory properties.
The procedure begins with an intensive phase, which lasts six weeks, followed by a maintenance phase, the duration of which is established according to medical practice.
During the intensive phase, a total plasma exchange is carried out every week and the withdrawn plasma is replaced with an albumin solution.
During the maintenance phase, low-volume plasma exchange is performed monthly and the withdrawn plasma is also replaced with an albumin solution.
AMBAR® slows disease progression in patients with mild-to-moderate Alzheimer's, reducing impairment in memory, orientation and judgment.
The opening of the first AMBAR® center in Barcelona reinforces Grifols' longstanding commitment to the Alzheimer's community. Moreover, Grifols intends to partner with other leading medical institutions to open centers in the EU, U.S. and China, applying AMBAR® in clinical practice.
AMBAR®: Research in Alzheimer's disease
More than 15 years of research in Alzheimer's, a disease that is estimated to affect 35 million people worldwide.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?